ANZ 1302A - Study to investigate the importance of aromatase inhibitor-induced musculoskeletal syndrome (AIMSS) in Australian women with breast cancer on aromatase inhibitors

ANZ 1302A - An online survey to evaluate the incidence and clinical impact of aromatase inhibitor-induced musculoskeletal syndrome (AIMSS) in Australian women with a diagnosis of breast cancer since 2007 being treated with an adjuvant aromatase inhibitor currently or since their diagnosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12613001009707

Enrollment

594

Registered

2013-09-11

Start date

2014-03-18

Completion date

2014-05-30

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to use an online survey to gather information on the incidence and clinical impact of Aromatase Inhibitor-Induced Musculoskeletal Syndrome (AIMSS) in Australian women. Who is it for? You may be eligible to join this study if you are 18 years or older, female, have had a diagnosis of early breast cancer since 2007 and have been taking an aromatase inhibitor at any time since your diagnosis. Trial details. Many women with breast cancer are prescribed aromatase inhibitors as part of their breast cancer treatment. It is known that some women experience side effects from aromatase inhibitors which disrupt their quality of life. Some women may even choose to stop taking their medication before they have completed the recommended course (usually five years). This survey will ask a number of questions about women's experiences with side effects from aromatase inhibitors. The survey focuses specifically on joint, muscle and tendon pain, stiffness and discomfort. Women who have not had joint or muscle symptoms are also welcome to take part. The survey will assist the researchers to: * Better understand how the side effects of aromatase inhibitors affect Australian women. * Investigate possible ways of reducing these symptoms * Look at ways of improving the way doctors and other health professionals measure women’s symptoms and their impact on quality of life.

Interventions

Online survey. Each participant will do the survey once. The questionnaire will take approximately 15 minutes. The first few questions are to check that the interview is right for the participant. The rest of the questions will ask about: * The participant's experience with aromatase inhibitors * Management of side effects of aromatase inhibitors with prescription medication * Management of side effects of aromatase inhibitors with over the counter medications * Management of side effects of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1) Must be female, >=18 years 2) Must have a diagnosis of Early Breast Cancer (stage 1-3) in 2007 or later 3) Must be taking adjuvant AI in any setting (up-front, switch, extended) currently or at any time since their breast cancer diagnosis 4) Must be able to provide informed consent

Exclusion criteria

1) Insufficient English language skills for participation 2) Diagnosis of DCIS only or with metastatic breast cancer

Outcome results